On February 15, Tess Mak, regional director of the world's top 500 enterprises AIA Group, Zeng Xiangbin of Dingrui Jinying Group, Wang Xiaidong, Executive Vice president of China Chuanshang Association and founder of Jixiang Holding Group, Yi Long, Secretary general of the National Hunan Chamber of Commerce and Industry, founder and CEO of Shuihan Capital, and other groups visited Shenzhen Cell Valley. Our chairman Professor Shi Yuanyuan, chief scientist Professor Wang Jianxun, Deputy General manager Tang Xiaomeng, chief medical consultant Dr. David Jin, General manager Director Wei Zheng, Chairman Assistant Fu Yuchen, marketing director Sun Rui, General Office director Wang Lu and other people warmly received.

Accompanied by Professor Shi Yuanyuan, the visiting guests visited the Shenzhen Cell Valley Wisdom Exhibition Hall and learned about the development process, core technologies and scientific research achievements of Shenzhen Cell Valley in detail. Then visited the production workshop and research and development laboratory, and had a more intuitive feeling of the actual operation process and production and quality management system.

At the symposium, Chairman Shi Yuanyuan first extended a warm welcome to the guests and introduced the company's core technical advantages in detail. He stressed that Shenzhen Cell Valley has a complete production and quality control system, and has been continuously deepening and making progress in the field of genetic modification and non-genetic modification cell therapy technology, aiming to contribute to the cause of human health. Professor Shi Yuanyuan further elaborated the important role of NK cells, stem cells and exosomes in promoting the development of the medical and health industry. NK cells are the most important "soldiers" responsible for killing aging, virus infection, tumor cells and other abnormal cells in the body. Mesenchymal stem cells (MSC) not only have the potential of multidirectional differentiation, but also are easy to transfect exogenous genes and have high efficiency and long-term expression. As an important carrier of information transmission between cells, exosomes have the effects of immune regulation, anti-inflammation, anti-fibrosis, inhibition of oxidative stress, and enhancement of angiogenesis. Subsequently, Chairman Shi Yuan shared policy expectations and industrial development trends. Shi Yuan said that as the country's emphasis on the big health industry continues to increase, relevant policy support will continue to strengthen, providing a good external environment for the research and development and application of cell therapy technology.

When talking about the cooperation with Hong Kong, Chairman Shi Yuanyuan said that Shenzhen and Hong Kong are close in geographical location and cultural friendship, and the two places have a broad basis for cooperation in science and technology, finance, medical care and other fields. Shenzhen Cell Valley has always attached great importance to the cooperation and exchanges with relevant institutions in Hong Kong, Shenzhen Cell Valley is preparing to build a subsidiary for the Greater Bay Area, especially Hong Kong business in Qianhai Free Trade Zone - Shenzhen-Hong Kong Cell Valley, aiming to promote the research and development and application of cell therapy technology through a closer and more targeted cooperation mechanism, and promote the coordinated development of the health industry of the two places

Director Mak of AIA introduced AIA's insurance services to high net worth individuals as Asia's largest life insurance group, and expressed the desire to further deepen cooperation with medical institutions and enterprises in the mainland, especially in Shenzhen. Director Mak said AIA looks forward to working closely with Shenzhen Cell Valley to provide more advanced and effective healthcare services to the Group's customers. Other guests also spoke and held in-depth discussions on how to strengthen the cooperation between Shenzhen and Hong Kong in the field of major health industry and promote the development and application of cell therapy technology. The participants agreed that the visit and exchange activities not only deepened mutual understanding and trust, but also laid a solid foundation for future cooperation.

The interaction between Shenzhen and Hong Kong enterprises not only demonstrated the leading position and influence of Shenzhen Cell Valley in the field of major health industry, but also injected new vitality into the cooperation and exchanges between Shenzhen and Hong Kong in this field. In the future, Shenzhen Cell Valley will continue to play its own advantages, continue to explore and innovate, and commit to making greater contributions to the cause of human health.